Shopping Cart
- Remove All
- Your shopping cart is currently empty
Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioedema.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $313 | In Stock | |
5 mg | $647 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,460 | In Stock | |
50 mg | $1,970 | In Stock | |
100 mg | $2,660 | In Stock |
Description | Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioedema. |
Targets&IC50 | β-FXIIa:140 pM(Kd) |
In vitro | Garadacimab (CSL312) demonstrates high affinity to activated βFXIIa with a KD of 140 pM. In an activated partial thromboplastin time (aPTT) assay with human plasma, Garadacimab exhibits potency. Notably, it displays high selectivity over a panel of relevant human serine proteases, including FVIIa, FIXa, FXa, FXIa, kallikrein, tissue plasminogen activator, activated protein C, and urokinase plasminogen activator[2]. |
In vivo | In male and female cynomolgus monkeys, Garadacimab (0.5, 1, and 3 mg/kg i.v. and 6 and 20 mg/kg s.c. over 8 weeks) shows a dose-dependent increase in plasma concentrations[1]. Garadacimab exhibits an inhibitory effect on FXII-mediated kallikrein activity. Moreover, it induces a clear dose-dependent prolongation of activated partial thromboplastin time (aPTT) with no associated effect on the prothrombin time[1]. |
Alias | CSL312 |
Molecular Weight | 146.5 kDa |
Cas No. | 2162134-62-3 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.